Provided by Tiger Trade Technology Pte. Ltd.

SIMCERE PHARMA

10.990
-0.110-0.99%
Volume:4.36M
Turnover:47.93M
Market Cap:28.22B
PE:17.45
High:11.100
Open:11.180
Low:10.960
Close:11.100
52wk High:14.247
52wk Low:9.070
Shares:2.57B
HK Float Shares:2.57B
Volume Ratio:0.75
T/O Rate:0.17%
Dividend:0.21
Dividend Rate:1.91%
EPS(LYR):0.630
ROE:18.77%
ROA:7.78%
PB:2.57
PE(LYR):17.45
PS:2.77

Loading ...

Simcere Zaiming Licenses Sim0660 to Roche in Deal Worth up to $1.53 Billion

Reuters
·
54 mins ago

Roche Signs Global Licensing Pact for Simcere's B-Cell Cancer Drug Candidate

Reuters
·
2 hours ago

Simcere Clinches US$75.00 Million Upfront, Up to US$1.46 Billion Milestone Deal With Roche for Tri-Specific Antibody SIM0660

Bulletin Express
·
3 hours ago

Simcere Pharma Enters Exclusive Global Licensing Pact with Roche for Novel Antibody Asset

Stock News
·
3 hours ago

Simcere Pharmaceutical - Enters Exclusive Global Licensing Agreement with Roche for Sim0660 on Sept 1, 2026

THOMSON REUTERS
·
3 hours ago

Simcere Pharmaceutical - Eligible for $75 Mln Upfront and up to $1.46 Bln in Milestone Payments

THOMSON REUTERS
·
3 hours ago

Simcere Pharmaceutical - Eligible for Tiered Royalties of up to Double Digits on Future Net Sales

THOMSON REUTERS
·
3 hours ago

Simcere Pharmaceutical Group (SEHK:2096) Stock Price Trails Margin Surge And DCF Gap

Simply Wall St.
·
Aug 21

Simcere Pharmaceutical Grants 795,000 RSUs Under 2021 Share Award Scheme

Reuters
·
Aug 21

Simcere Pharmaceutical Group's H1 Attributable Profit Rises 38%

MT Newswires Live
·
Aug 21

Simcere Pharmaceutical reshuffles joint company secretaries; wins three-year Listing Rules waiver

Bulletin Express
·
Aug 20

Simcere Pharma initiates up to RMB 1.00 billion share buyback, covering 10% of issued capital

Bulletin Express
·
Aug 20

Simcere Pharma's Half-Year Profit Jumps 48.7% on Adjusted Basis

Stock News
·
Aug 20

Simcere Pharma Appoints Zhu Da as Joint Company Secretary

Stock News
·
Aug 20

China's Simcere Pharmaceutical H1 Revenue Rises on Neuroscience, Autoimmune Drugs Strength

Reuters
·
Aug 20

Simcere Pharmaceutical Posts HY Net Income Attributable of RMB 829 MLN

Reuters
·
Aug 20

Simcere Pharmaceutical Files Board, Committee Member List with Disclosure Responsibilities

Reuters
·
Aug 20

Simcere Pharmaceutical Launches Open-Market Share Buyback of up to RMB 1 Billion

Reuters
·
Aug 20

Simcere Pharmaceutical - Share Repurchase Period from Aug 21, 2026 Until Next AGM or Earlier if Authority Revoked

THOMSON REUTERS
·
Aug 20

Simcere Pharmaceutical - to Repurchase Shares in Open Market up to Rmb1,000 Mln

THOMSON REUTERS
·
Aug 20